Lupi-Fsh 150 Injection contains Urofollitropin 150 IU, a purified follicle-stimulating hormone (FSH) derived from the urine of postmenopausal women. It is indicated for use in assisted reproductive technologies, including controlled ovarian stimulation in women undergoing in vitro fertilization (IVF) or other assisted reproductive procedures. Urofollitropin acts by stimulating the growth and development of ovarian follicles, promoting folliculogenesis and enhancing endogenous estrogen production. This injectable preparation is administered subcutaneously or intramuscularly under medical supervision, with dosage individualized based on patient response and treatment protocol. Lupi-Fsh 150 Injection is contraindicated in patients with primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, ovarian cysts unrelated to polycystic ovary syndrome, or hypersensitivity to the active substance or excipients. Careful monitoring of ovarian response via ultrasound and serum estradiol levels is essential to minimize the risk of ovarian hyperstimulation syndrome (OHSS). Adverse effects may include injection site reactions, headache, abdominal discomfort, and rarely, OHSS. This medication should be used with caution in patients with a history of thromboembolic disorders. Lupi-Fsh 150 Injection should be prescribed and administered by healthcare professionals experienced in fertility treatments to ensure optimal outcomes and patient safety.

Dosage & How to Use